Can a medical assistant give allergy shots? In the UK, allergen immunotherapy (allergy shots) is a specialist procedure governed by strict regulatory and safety requirements. Unlike in the United States, 'medical assistant' is not a formally regulated professional title in UK healthcare. Allergy shots — specifically subcutaneous immunotherapy (SCIT) — must be administered by appropriately trained, registered clinicians such as registered nurses or doctors, within a clinical setting equipped for emergency management, including anaphylaxis. This article explains who is qualified to give allergy shots in the UK, the relevant legal framework, and what patients should expect from a safe, accredited allergy service.

Who Is Qualified to Administer Allergy Immunotherapy in the UK

In the UK, allergen immunotherapy — commonly referred to as allergy shots or allergen immunotherapy (AIT) — is a specialist medical procedure that must be administered by appropriately qualified and registered healthcare professionals. Subcutaneous immunotherapy (SCIT) injections are typically carried out by registered nurses, specialist allergy nurses, Nursing Associates (registered with the Nursing and Midwifery Council), or doctors working within a supervised clinical environment.

It is important to distinguish SCIT from sublingual immunotherapy (SLIT), which is administered by the patient at home and carries a lower risk of systemic reactions. SCIT, by contrast, must always be given in a clinical setting with full resuscitation facilities, owing to the recognised risk of anaphylaxis.

The Medicines and Healthcare products Regulatory Agency (MHRA) classifies allergen immunotherapy products as prescription-only medicines (POMs). They can only be prescribed by a qualified prescriber — such as a consultant allergist working in secondary care — and must be administered in settings equipped to manage adverse reactions, including anaphylaxis. Initiation of SCIT and the management of dose schedules are almost always undertaken within specialist secondary care allergy or immunology services. Any delivery in primary care should occur only under a formal shared-care arrangement that meets all relevant BSACI standards, including the immediate availability of full resuscitation facilities and trained personnel.

The British Society for Allergy and Clinical Immunology (BSACI) provides clear guidance that SCIT should only be given where intramuscular (IM) adrenaline (1:1000), oxygen, intravenous access, and full resuscitation equipment are immediately available, alongside personnel trained to use them. This reflects the fact that systemic allergic reactions can occur even in patients who have previously tolerated injections without incident. The Resuscitation Council UK anaphylaxis guideline provides the authoritative framework for emergency management in these settings.

The Role of a Medical Assistant in Allergy Care Settings

The term 'medical assistant' is not a formally regulated professional title in the UK in the same way it is in the United States. In UK healthcare settings, the closest equivalent roles include healthcare assistants (HCAs), clinical support workers, or medical secretaries. Unlike Nursing Associates (registered with the NMC) or Physician Associates (moving towards GMC regulation), these roles are not registered with a statutory regulatory body and do not hold independent clinical accountability.

Within an allergy clinic, a healthcare support worker may perform a range of valuable tasks, including:

• Preparing the clinical environment and ensuring resuscitation equipment is checked and available

• Recording patient observations such as blood pressure and peak flow before and after injections

• Documenting patient responses and flagging concerns to the supervising clinician

• Supporting patient education by providing written information about what to expect during treatment

Regarding the actual administration of allergen immunotherapy injections: whilst UK law (Human Medicines Regulations 2012) permits a suitably trained, competent person to administer a medicine under a Patient Specific Direction (PSD), BSACI best practice is that SCIT is administered only by appropriately trained, registered clinicians — such as registered nurses, Nursing Associates, or doctors — with immediate access to resuscitation facilities. This is not merely an organisational preference; it is a direct patient safety requirement. The risk of anaphylaxis demands that the administering clinician is trained to recognise and respond to systemic reactions promptly and competently.

Nursing Associates and Physician Associates may have a role in allergy services subject to demonstrated competency, appropriate governance frameworks, and organisational policy, but their involvement must be clearly defined and supervised.

UK Guidelines and Regulatory Framework for Allergy Injection Administration

The regulatory framework governing allergy immunotherapy in the UK is robust and multi-layered. The MHRA oversees the licensing of allergen immunotherapy products. It is important to note that many SCIT preparations do not hold a UK marketing authorisation and are instead supplied as unlicensed medicines on a named-patient basis under MHRA guidance on 'Specials'. Unlicensed 'specials' are prepared specifically for individual patients and are subject to strict handling, storage, and administration protocols. Where a UK-licensed SCIT product exists, the relevant Summary of Product Characteristics (SmPC), available via the electronic Medicines Compendium (EMC), should be consulted for product-specific requirements.

BSACI clinical guidelines recommend that SCIT is delivered within specialist secondary care or accredited allergy services, rather than in primary care settings without appropriate infrastructure. Any shared-care arrangement in primary care is exceptional and must fully meet BSACI standards. The 30-minute post-injection observation period is designed to detect immediate systemic reactions; patients should also be aware that, rarely, reactions may occur after leaving the clinic (see patient safety section below).

The Human Medicines Regulations 2012 govern who may administer prescription-only medicines. Two key legal frameworks are relevant:

• A Patient Group Direction (PGD) authorises specified registered healthcare professionals to supply or administer a medicine to a group of patients meeting defined criteria, without an individual prescription. However, PGDs are not appropriate for SCIT because immunotherapy requires individually titrated dosing — a requirement incompatible with the PGD model. This is consistent with NICE Medicines Practice Guideline MPG2.

• A Patient Specific Direction (PSD) is a written instruction from a prescriber for a named patient. UK law permits a suitably trained, competent person to administer under a PSD; however, for SCIT, BSACI best practice requires this to be a trained, registered clinician.

Clinics operating outside these legal and professional frameworks risk regulatory sanction and, more critically, patient harm. Suspected adverse reactions to allergen immunotherapy products should be reported to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk).

Training and Supervision Requirements for Allergy Shot Procedures

For registered healthcare professionals authorised to administer allergy immunotherapy, specific training and ongoing competency assessment are essential. The BSACI and the Royal College of Physicians recommend that nurses and other clinicians administering SCIT complete formal training in allergen immunotherapy, which covers:

• Correct injection technique (subcutaneous administration into the outer upper arm)

• Dose adjustment protocols, particularly following missed appointments or adverse reactions

• Pre-injection safety checks, including withholding the injection if the patient is acutely unwell, febrile, or has poorly controlled asthma; local protocols may specify FEV1 or peak flow thresholds below which treatment should be deferred

• Recognition of local and systemic reactions, including early signs of anaphylaxis

• Emergency management, including the administration of IM adrenaline (1:1000), antihistamines, oxygen, and intravenous fluids, and the immediate escalation to emergency services

• Mandatory periodic updates in basic and intermediate life support (BLS/ILS) and anaphylaxis management, in line with Resuscitation Council UK guidance, including participation in simulation drills

Key contraindications and precautions that clinicians must be aware of include: uncontrolled or severe asthma, initiation of SCIT during pregnancy, and concurrent use of beta-blockers or ACE inhibitors (which may impair the response to adrenaline and are of particular concern in venom immunotherapy). These factors must be assessed at each appointment.

Supervision arrangements must be clearly defined within each clinical setting. A consultant allergist or appropriately trained clinician should provide clinical oversight, and written protocols must be in place for managing adverse events. Regular competency reviews and participation in clinical audit are considered best practice.

Even experienced registered nurses new to allergy services should undergo a supervised induction period before administering injections independently. Training is an ongoing professional responsibility, particularly as allergen products and dosing schedules may vary between patients and manufacturers.

Patient Safety Considerations When Receiving Allergy Immunotherapy

Patient safety is the central concern underpinning all guidance on allergy immunotherapy administration. Systemic reactions, including anaphylaxis, can occur with any dose, even in patients who have completed the build-up phase and are receiving maintenance doses. Every injection appointment therefore carries inherent risk that must be actively managed.

Key safety measures that patients should expect at every appointment include:

• Pre-injection assessment: A clinician should review any recent symptoms, illnesses, new medications, or changes in asthma control before proceeding. Poorly controlled asthma is a recognised risk factor for severe reactions, and the injection may need to be deferred.

• Correct dose verification: The dose must be checked against the patient's individual treatment schedule, particularly if appointments have been missed or a reaction has previously occurred.

• Post-injection observation: Patients must remain in the clinic for a minimum of 30 minutes after each injection, under clinical supervision, to allow detection of immediate systemic reactions.

• Access to emergency medication and equipment: Clinics must have IM adrenaline (1:1000) ampoules, oxygen, intravenous access and fluids, and full resuscitation equipment immediately available. Adrenaline auto-injectors are not a substitute for these in a clinical setting.

• Avoidance of co-factors: Patients should be advised to avoid strenuous exercise, alcohol, and hot baths or saunas for a period before and after each injection, as these may increase the risk of a systemic reaction. Specific timeframes should be confirmed with the treating clinic.

Patients themselves play an important role in safety. They should inform the administering clinician of any recent infections, new medications, or worsening allergy or asthma symptoms before each appointment.

After leaving the clinic: although rare, systemic reactions can occasionally occur after the observation period. If you develop symptoms such as urticaria, throat tightening, wheezing, dizziness, or difficulty breathing after leaving, use your prescribed adrenaline auto-injector immediately and call 999. Do not drive yourself to hospital. Any suspected adverse reaction to an allergen immunotherapy product should also be reported to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk).

When to Seek Advice From a Specialist Allergy Clinic

If you are considering allergen immunotherapy, or are already undergoing treatment and have concerns about how it is being managed, seeking advice from a specialist allergy clinic accredited under the BSACI Allergy Service Accreditation Scheme (ASAS) is strongly recommended. The ASAS helps patients and referrers identify services that meet defined standards for safety, staffing, and facilities. In the UK, referral to a specialist allergy service is typically made through your GP, and waiting times can vary depending on your NHS region.

Call 999 immediately if you or someone with you develops signs of anaphylaxis — including difficulty breathing, throat tightening, swelling of the face or tongue, collapse, or loss of consciousness — whether during the clinic visit or after leaving.

You should seek prompt advice from a specialist or contact your GP if:

• You experience local reactions (significant swelling or redness at the injection site) that are increasing in severity

• You develop systemic symptoms after an injection, such as urticaria, throat tightening, wheezing, or dizziness — even if mild

• Your asthma symptoms worsen during the course of immunotherapy

• You are unsure whether the setting in which you are receiving injections has adequate emergency facilities or qualified staff

• You have been offered allergy shots in a setting that does not appear to follow the 30-minute observation protocol

It is entirely reasonable to ask questions about the qualifications of the person administering your injections and the emergency protocols in place. A reputable allergy service will welcome such questions. If you have any doubt about the safety or appropriateness of your treatment setting, raise concerns with your GP or contact NHS 111 for guidance. Any suspected adverse reaction to an allergen immunotherapy product should be reported to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk). Your safety throughout the immunotherapy process is paramount.

Frequently Asked Questions